1. Home
  2. CYPH vs HPI Comparison

CYPH vs HPI Comparison

Compare CYPH & HPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cypherpunk Technologies Inc.

CYPH

Cypherpunk Technologies Inc.

N/A

Current Price

$2.00

Market Cap

321.1M

Sector

Health Care

ML Signal

N/A

HPI

John Hancock Preferred Income Fund of Beneficial Interest

N/A

Current Price

$13.16

Market Cap

360.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CYPH
HPI
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
321.1M
360.0M
IPO Year
2019
2002

Fundamental Metrics

Financial Performance
Metric
CYPH
HPI
Price
$2.00
$13.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 13.3M
115.4K
Earning Date
11-16-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 103.87
N/A
EPS
N/A
★ N/A
Revenue
★ $1,500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$408.92
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$13.10
52 Week High
$4.19
$17.10

Technical Indicators

Market Signals
Indicator
CYPH
HPI
Relative Strength Index (RSI) 40.45 39.85
Support Level $0.65 $13.10
Resistance Level $3.42 $16.39
Average True Range (ATR) 0.39 0.21
MACD -0.11 0.05
Stochastic Oscillator 7.69 12.27

Price Performance

Historical Comparison
CYPH
HPI

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

About HPI John Hancock Preferred Income Fund of Beneficial Interest

John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.

Share on Social Networks: